CommercialCoverageMedium impact
06.02.46a, Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for Diagnosis of Genetic Disorders
Independence Blue Cross·Pediatrics, Neurology, Oncology·Medical Policy
Effective date
Jan 1, 2024
We identified it
Jun 19, 2026
Summary
A new medical policy for Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for genetic disorder diagnosis has been updated for commercial plans. This policy establishes coverage criteria and billing guidelines for these advanced genetic testing procedures effective January 1, 2024.
Action Required
Immediately: Billing team should review the full policy details at the provided URL to understand coverage criteria for rapid whole exome and genome sequencing. Update billing procedures and prior authorization requirements for genetic testing services. Ensure proper documentation requirements are met for these specialized diagnostic tests.